1. What is ARA290?
ARA290 (also known as Cibinetide or pHBSP) is a synthetic peptide derived from erythropoietin (EPO). It was designed to preserve tissue-protective and anti-inflammatory properties of EPO without stimulating red blood cell production. ARA290 primarily interacts with the innate repair receptor (IRR), which is upregulated during tissue stress or injury. Research has explored its potential roles in neuroprotection, inflammation control, and tissue repair.
2. ARA290 Structure
Sequence: ZEQLERALNSS
Molecular Formula: C₅₁H₈₄N₁₆O₂₁
Molecular Weight: 1257.3 g/mol
PubChem CID: 91810664
CAS No: 1208243-50-8
Synonyms: cibinetide,PH-BSP
3. ARA290 Research
ARA290: Tissue-Protection Research Peptide
ARA290 has been studied for its selective action on the IRR receptor complex (EPOR + CD131). Unlike EPO, it does not induce erythropoiesis, making it of interest in experimental studies of tissue injury and inflammation 【1】.
【1】 Neuropathy & Nerve Research
Early clinical investigations in conditions such as diabetes-related neuropathy and sarcoidosis-associated neuropathy have reported exploratory findings, including reductions in pain scores and improved nerve fiber markers. These results remain preliminary and require further validation 【2】.
【2】 Kidney & Tissue Models
Research has evaluated ARA290 in models of renal stress and tissue repair, where improvements in inflammatory biomarkers (IL-6, TNF-α) and reduced tissue fibrosis were observed in preclinical and early human studies 【3】.
【3】 Cardio-Metabolic Studies
Preclinical and exploratory clinical research has suggested possible roles in systemic inflammation, insulin sensitivity, and vascular health. However, these observations are investigational and not yet validated for clinical use.
【4】 Mechanism & Research Profile
l Receptor specificity: Acts on the IRR complex rather than EPO’s hematopoietic pathway.
l Inflammation control: Reported to downregulate cytokines (e.g., IL-6, TNF-α) in research contexts.
l Safety in studies: Early-stage research indicates tolerability, with no significant erythropoietic effects reported.
✅ Why Researchers Study ARA290
l Investigated for nerve fiber protection
l Studied in tissue repair and fibrosis models
l Explored for systemic inflammation modulation
l Differentiated from EPO by non-erythropoietic receptor targeting
4. Future ARA290 Research
Quotations from published literature illustrate ongoing interest:
“ARA290 appears to be safe in patients with sarcoidosis and to reduce neuropathic symptoms.”
— Mol Med, 2012
“Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect.”
— IOVS corneal nerve study
Future studies may further explore:
l Neuropathy and nerve regeneration research
l Tissue repair and wound-healing models
l Inflammation and metabolic syndrome pathways
l Expanded peptide analogs for optimized receptor targeting
5. How Does ARA290 Work?
ARA290 (pHBSP) is derived from EPO’s Helix B surface region but lacks erythropoietic activity. Instead, it interacts with the Innate Repair Receptor (IRR), a heteromer of EPOR and CD131, which is activated during injury or inflammation.
l Targeted signaling: Triggers cascades that support anti-inflammatory and cytoprotective responses.
l Tissue specificity: Activation occurs predominantly in stressed or damaged tissues, minimizing off-target effects.
l Research relevance: Models suggest possible applications in nerve protection, vascular repair, and inflammation control, though therapeutic uses are not approved.
⚠ Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
